Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (GB:0K1R)
LSE:0K1R
0K1R Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.50 - $27.10
Previous CloseN/A
Volume66.00
Average Volume (3M)2.49K
Market Cap
$1.49B
Enterprise Value$969.97M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.96
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.31
Shares Outstanding79,212,746
10 Day Avg. Volume1,319
30 Day Avg. Volume2,494
Standard Deviation0.30
R-Squared0.03
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4839.32
Price to Cash Flow (P/CF)-5.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-962.28
Enterprise Value/Ebitda-3.84
Forecast
1Y Price Target
$41.69Price Target Upside112.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe THRIVE trial achieved all its primary/secondary endpoints at 15 weeks with a high level of statistical significance.
Financial PositionVRDN is well funded with a balance of cash and equivalents of $753MM at the end of Q3 providing runway into H2:27.
Market PotentialDespite a significant upside move, there is still significant value upside given VRDN's potential in the growing ~$2B TED market.
Bears Say
Efficacy And TolerabilityLinsitinib's efficacy was meaningfully lower than that of Viridian's veligrotug in the pivotal THRIVE study, with a slower onset of efficacy.
Financial RiskA miss could delay the filing, and we see a negative ~$15 impact to our valuation in this scenario.
Market CompetitionLinsitinib is not considered meaningfully competitive with other IGF-1R inhibitors for moderate to severe TED due to its subpar efficacy.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.38% Insiders
23.20% Mutual Funds
<0.01% Other Institutional Investors
59.91% Public Companies and Individual Investors
0K1R FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest share price was $11.50 and its highest was $27.10 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market cap is $1.49B.
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 91 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Nov 12, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$1.057 by -$0.093.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 79,212,746 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$1.15 in its last earnings report, missing expectations of -$1.057. Following the earnings report the stock price went down -7.623%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Among the largest hedge funds holding Viridian Therapeutics’s share is Fairmount Funds Management Llc. It holds Viridian Therapeutics’s shares valued at 78M.
---
Viridian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.69 (112.05% Upside)
$41.69 (112.05% Upside)
Blogger Sentiment
Bullish
GB:0K1R Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.75%
12-Months-Change
Fundamentals
Return on Equity
-51.88%
Trailing 12-Months
Asset Growth
134.79%
Trailing 12-Months
Company Description
Viridian Therapeutics
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
---
0K1R Stock 12 Month Forecast
Average Price Target
$41.69
▲(112.05% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Regeneron
―
Ultragenyx Pharmaceutical
―
Argenx Se
―
Immunovant
―
Best Analysts Covering 0K1R
1 Year
1 Year Success Rate
21/38 ratings generated profit
1 Year Average Return
+4.78%
reiterated a buy rating 29 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 55.26% of your transactions generating a profit, with an average return of +4.78% per trade.
---